Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2016 | Prevention strategies for Alzheimer’s disease

Philip Scheltens • 29 May 2016
EAN 2016
Alzheimer’s Disease

At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Philip Scheltens, MD, PhD, from VU University Medical Center, Amsterdam, the Netherlands, discusses the clinical development of prevention strategies, including for reducing the development amyloid plaques in preclinical stages, for patients with Alzheimer’s disease.

More from Philip Scheltens

Alzheimer's early diagnosis: challenges and benefits
1:03
Alzheimer's early diagnosis: challenges and benefits
Philip Scheltens • 19 Mar 2019
The heterogeneity of Alzheimer's disease
0:46
The heterogeneity of Alzheimer's disease
Philip Scheltens • 19 Mar 2019
A biological definition of Alzheimer's disease
1:45
A biological definition of Alzheimer's disease
Philip Scheltens • 19 Mar 2019
Cerebrospinal fluid (CSF) and imaging biomarkers for the differential diagnosis of dementia
1:06
Cerebrospinal fluid (CSF) and imaging biomarkers for the differential diagnosis of dementia
Philip Scheltens • 24 Jun 2017

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals